Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05844111 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05844111 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 6 participants.
The verdict
NCT05844111, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The main objective of this study is to determine the mass balance, routes of elimination, and pharmacokinetics of \[14C\]-BGB-11417 in healthy male participants along with determining the concentrations of radioactivity in plasma, fecal and urinary elimination of total radioactivity.
Interventions
- DRUG [14C]-BGB-11417
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2023-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05844111
The ClinicalTrials.gov registry entry for NCT05844111 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-BGB-11417 is the first listed.
NCT05844111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05844111 about?
NCT05844111 is a clinical study titled "A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417". The main objective of this study is to determine the mass balance, routes of elimination, and pharmacokinetics of \[14C\]-BGB-11417 in healthy male participants along with determining the concentrations of radioactivity in plasma, fecal and urinary elimination of total radioactivity.
What is the current status of trial NCT05844111?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-05-22. Estimated completion is 2023-06-18.
What interventions are being tested in trial NCT05844111?
The interventions under investigation include: [14C]-BGB-11417 (DRUG).
Who is sponsoring clinical trial NCT05844111?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.